Related Experiment Video
Updated: May 24, 2026
08:28
Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers
Published on: September 19, 2017
G-quadruplexes: targets and tools in anticancer drug design
1Department of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Łódź, Poland. mduchler@cbmm.lodz.pl
Journal of Drug Targeting
|March 20, 2012
Summary
G-quadruplex structures in DNA and RNA offer new anticancer strategies. Stabilizing these structures can halt cancer cell growth and induce death, making them key targets and tools for drug development.
Area of Science:
- Molecular Biology
- Biochemistry
- Genetics
Background:
- Guanosine (G)-rich sequences form G-quadruplex structures, characterized by stacked G-tetrads.
- These structures are prevalent in telomeric DNA, RNA transcripts, and oncogene regulatory regions.
Purpose of the Study:
- To review the application of G-quadruplexes in anticancer therapies.
- To discuss the mechanisms underlying G-quadruplex-mediated anticancer effects.
Main Methods:
- Literature search of the Medline database.
- Keywords used: "G-rich oligonucleotide (GRO)", "G-tetrad", and "G-quadruplex".
Main Results:
- G-quadruplex stabilization by drugs inhibits telomere elongation and oncogene transcription/translation.
- Stabilization leads to cancer cell senescence and apoptosis.
- G-rich oligonucleotides (GROs) form stable G-quadruplex structures and exhibit anticancer activity, with some showing promise in clinical studies.
Conclusions:
- G-quadruplexes serve as both therapeutic targets and drug development tools in oncology.
- Further research into G-quadruplexes holds significant potential for novel anticancer drug discovery.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...